Last 48 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 55.29 | 41.74 | 32.64 | 37.79 | 33.98 | 30.05 | 45.50 | 46.01 | 40.56 | 54.53 | 63.82 | 48.10 | 43.83 | 46.42 | 46.82 | 43.26 | 38.69 | 30.36 | 44.84 | 60.75 | 45.95 |
| — | +38.9% | -28.3% | -17.8% | -16.2% | -44.9% | -28.7% | -4.4% | -7.5% | +17.5% | +36.3% | +11.2% | +13.3% | +52.9% | +4.4% | -28.8% | -15.8% | -16.5% | +26.7% | +10.7% | -27.1% | |
| P/S Ratio | 8.61 | 7.34 | 5.37 | 6.21 | 5.93 | 5.20 | 5.85 | 8.06 | 7.37 | 8.65 | 10.57 | 9.02 | 9.45 | 9.56 | 9.16 | 6.28 | 6.78 | 7.43 | 10.84 | 12.29 | 11.42 |
| — | +41.2% | -8.2% | -23.0% | -19.6% | -39.9% | -44.6% | -10.6% | -22.0% | -9.6% | +15.4% | +43.6% | +39.3% | +28.7% | -15.5% | -48.9% | -40.6% | -20.9% | +36.3% | +32.3% | +20.2% | |
| P/B Ratio | 8.61 | 8.56 | 6.07 | 6.30 | 6.25 | 5.44 | 6.09 | 9.00 | 8.01 | 9.42 | 10.97 | 9.17 | 9.85 | 10.50 | 9.45 | 6.63 | 7.54 | 9.45 | 13.42 | 15.34 | 14.65 |
| — | +57.4% | -0.4% | -30.0% | -21.9% | -42.3% | -44.5% | -1.8% | -18.7% | -10.3% | +16.1% | +38.3% | +30.7% | +11.1% | -29.6% | -56.8% | -48.5% | -29.3% | +14.9% | +32.0% | +20.9% | |
| P/FCF | 56.43 | 79.20 | 96.11 | 28.58 | 35.61 | 39.08 | 70.32 | 70.84 | 55.75 | 93.66 | 266.32 | 50.63 | 52.59 | 76.86 | 117.09 | 32.73 | 41.92 | 53.55 | 91.38 | 106.26 | 64.63 |
| — | +102.7% | +36.7% | -59.7% | -36.1% | -58.3% | -73.6% | +39.9% | +6.0% | +21.9% | +127.4% | +54.7% | +25.5% | +43.5% | +28.1% | -69.2% | -35.1% | -31.1% | -41.8% | +86.9% | -11.8% | |
| EV / EBITDA | 35.16 | 35.56 | 20.23 | 23.98 | 21.62 | 19.69 | 24.11 | 28.35 | 26.26 | 35.56 | 44.75 | 31.31 | 30.49 | 32.02 | 32.21 | 22.31 | 20.93 | 22.18 | 35.67 | 41.10 | 37.35 |
| — | +80.6% | -16.1% | -15.4% | -17.7% | -44.6% | -46.1% | -9.5% | -13.9% | +11.1% | +38.9% | +40.3% | +45.7% | +44.4% | -9.7% | -45.7% | -44.0% | -21.4% | +41.0% | +16.6% | +0.8% | |
| EV / EBIT | 42.25 | 35.56 | 25.79 | 30.05 | 26.91 | 25.02 | 36.61 | 36.32 | 33.06 | 46.35 | 56.45 | 38.19 | 36.42 | 37.80 | 40.06 | 33.03 | 32.90 | 24.60 | 40.74 | 47.83 | 43.62 |
| — | +42.1% | -29.6% | -17.3% | -18.6% | -46.0% | -35.1% | -4.9% | -9.2% | +22.6% | +40.9% | +15.6% | +10.7% | +53.7% | -1.7% | -30.9% | -24.6% | -22.2% | +35.8% | +6.0% | -19.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.9% | 37.7% | 35.1% | 37.8% | 36.5% | 35.7% | 33.3% | 36.7% | 35.5% | 32.9% | 33.3% | 38.1% | 38.7% | 38.7% | 37.8% | 37.2% | 39.0% | 41.4% | 39.6% | 40.1% | 40.8% |
| — | +5.8% | +5.3% | +3.0% | +2.8% | +8.2% | +0.2% | -3.8% | -8.3% | -15.0% | -12.0% | +2.5% | -0.6% | -6.5% | -4.5% | -7.4% | -4.6% | -5.1% | -2.6% | +10.1% | +17.3% | |
| Operating Margin | 20.1% | 20.5% | 21.0% | 19.5% | 21.6% | 20.6% | 18.4% | 22.8% | 22.5% | 18.6% | 18.3% | 23.3% | 25.6% | 24.8% | 23.4% | 22.8% | 27.3% | 29.0% | 26.0% | 24.8% | 26.0% |
| — | -0.6% | +14.0% | -14.6% | -3.9% | +10.8% | +0.7% | -2.2% | -12.1% | -25.0% | -21.9% | +2.0% | -6.5% | -14.4% | -9.9% | -8.0% | +5.2% | +0.1% | -3.4% | +17.7% | +33.4% | |
| Net Margin | 16.1% | 17.7% | 16.4% | 16.4% | 17.4% | 17.2% | 12.9% | 17.4% | 18.2% | 15.9% | 16.6% | 18.7% | 21.6% | 20.6% | 19.6% | 14.5% | 17.6% | 24.4% | 24.1% | 20.3% | 24.9% |
| — | +2.6% | +27.7% | -5.6% | -4.4% | +8.5% | -22.4% | -7.1% | -15.6% | -22.9% | -15.2% | +28.7% | +22.8% | -15.8% | -19.0% | -28.2% | -29.3% | -5.6% | +7.2% | +19.5% | +65.6% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.9% | 5.1% | 4.5% | 4.2% | 4.7% | 4.7% | 3.3% | 4.8% | 5.1% | 4.2% | 4.1% | 4.8% | 5.7% | 5.6% | 5.1% | 4.0% | 4.9% | 7.9% | 7.5% | 6.5% | 8.3% |
| — | +9.6% | +34.5% | -11.4% | -8.3% | +10.9% | -19.3% | +0.5% | -11.2% | -24.6% | -19.1% | +19.3% | +16.6% | -29.2% | -31.2% | -38.6% | -40.6% | -18.2% | -9.2% | +18.2% | +67.5% | |
| ROA | 12.5% | 3.8% | 3.3% | 3.2% | 3.5% | 3.5% | 2.5% | 3.6% | 3.8% | 3.1% | 3.1% | 3.6% | 4.3% | 4.2% | 3.8% | 3.0% | 3.6% | 5.7% | 5.3% | 4.6% | 5.8% |
| — | +8.1% | +33.9% | -11.3% | -8.5% | +10.9% | -20.3% | -1.6% | -12.6% | -25.2% | -18.7% | +21.6% | +20.3% | -25.9% | -27.5% | -35.1% | -37.5% | -14.2% | -3.8% | +25.0% | +74.7% | |
| ROIC | 17.5% | 4.8% | 4.8% | 4.3% | 4.8% | 4.5% | 3.8% | 5.1% | 5.0% | 4.1% | 4.0% | 5.5% | 6.3% | 6.3% | 5.8% | 5.8% | 6.9% | 8.3% | 7.2% | 7.3% | 7.6% |
| — | +6.3% | +27.7% | -14.3% | -4.8% | +10.0% | -6.1% | -9.0% | -20.4% | -35.4% | -30.7% | -5.1% | -8.4% | -24.5% | -19.2% | -19.7% | -9.7% | -8.8% | -13.9% | +22.6% | +43.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.10 | 0.11 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.12 | 0.14 | 0.14 | 0.14 | 0.14 |
| — | +0.8% | -6.4% | -10.3% | -11.9% | -14.1% | -1.2% | +5.1% | +3.5% | +6.4% | +1.0% | -9.4% | -11.9% | -17.4% | -20.5% | -15.0% | -15.3% | -12.7% | -19.0% | -20.7% | -24.3% | |
| Debt / EBITDA | 0.56 | 1.74 | 1.43 | 1.58 | 1.37 | 1.52 | 1.80 | 1.43 | 1.47 | 1.83 | 1.89 | 1.50 | 1.35 | 1.41 | 1.58 | 1.65 | 1.38 | 1.31 | 1.53 | 1.51 | 1.48 |
| — | +14.7% | -20.8% | +10.2% | -6.3% | -17.0% | -4.5% | -4.4% | +8.3% | +30.2% | +19.4% | -9.2% | -1.9% | +7.4% | +3.2% | +9.1% | -6.7% | -2.2% | -0.3% | -30.0% | -36.7% | |
| Current Ratio | 3.02 | 2.82 | 2.71 | 3.02 | 2.87 | 2.78 | 2.77 | 2.79 | 3.00 | 2.34 | 2.61 | 2.88 | 3.70 | 3.66 | 3.62 | 3.70 | 3.80 | 3.13 | 2.89 | 2.93 | 2.86 |
| — | +1.5% | -2.1% | +8.1% | -4.4% | +18.8% | +6.0% | -3.0% | -18.8% | -36.1% | -27.9% | -22.1% | -2.6% | +16.9% | +25.3% | +26.1% | +32.7% | +0.3% | +5.2% | +7.5% | +3.4% | |
| Quick Ratio | 2.34 | 2.12 | 2.04 | 2.34 | 2.18 | 2.08 | 2.03 | 2.11 | 2.23 | 1.68 | 1.95 | 2.24 | 2.89 | 2.78 | 2.79 | 2.90 | 2.89 | 2.41 | 2.18 | 2.30 | 2.23 |
| — | +1.9% | +0.5% | +11.1% | -2.0% | +24.1% | +4.2% | -5.6% | -22.9% | -39.7% | -30.1% | -22.9% | -0.1% | +15.8% | +27.9% | +26.3% | +29.8% | +0.5% | +3.4% | +9.8% | +5.7% | |
| Interest Coverage | 998.67 | — | — | — | 1741.00 | 1571.00 | 277.25 | — | 236.00 | 86.80 | 85.93 | 153.91 | 65.48 | 72.12 | 72.77 | 81.44 | 65.86 | 127.22 | 90.24 | 59.68 | 107.53 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WST stock.
West Pharmaceutical Services, Inc.'s current P/E is 55.3x. The average P/E over the last 4 quarters is 36.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
West Pharmaceutical Services, Inc.'s current operating margin is 20.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking West Pharmaceutical Services, Inc.'s business trajectory between earnings reports.